In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

The new ESC Guidelines on non cardiac surgery: how to individualise cardiac risk assessment and treatment?

ESC webinar

18/03/2015 00:00 18/03/2015 00:00 Europe/Paris The new ESC Guidelines on non cardiac surgery: how to individualise cardiac risk assessment and treatment?

Access event page

European Society of Cardiology DD/MM/YYYY
Cardiovascular Disease in Primary Care
Non-cardiac Surgery\Pre-surgical Assessment

Watch part one of the recording


Watch part two of the recording


Bernard Iung and Luc Pierard focus on the implementation of the latest ESC Guidelines on Non-Cardiac Surgery: Cardiovascular Assessment & Management into your daily clinical practice. 

During this session, the Presenters will:

  • discuss risk stratification and indications for investigations in a patient with risk factors who should undergo non-cardiac surgery
  • review indications for myocardial revascularization in a patient with coronary artery disease before non-cardiac surgery
  • discuss the management of a patient with severe aortic stenosis who should undergo non-cardiac surgery.

ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
Practice Guideline Track on Non Cardiac Surgery

The ESC Webinars are designed to help you improve your daily practice!

The format includes a case based presentation, online assessment and live discussions with the 2 key opinion leaders who will give you some useful tips for your daily clinical practice.



This programme is supported by Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo Europe GmbH, Novartis Pharma AG and Servier in the form of unrestricted educational grants.

The scientific programme has not been influenced in any way by its sponsors.